Bioxyne Limited (ASX:BXN) Upgrades FY2025 Revenue Guidance
Revenue Guidance Upgrade
Bioxyne Limited (ASX:BXN) has upgraded its full-year FY2025 revenue guidance from $25 million to $28 million.
Financial Performance
The company’s revenue for H1 FY2025 reached $12.6 million, marking a 267% increase compared to the previous half. Revenue for H2 FY2025 is expected to be $15.4 million, a 226% rise on the corresponding period in H2 FY2024.
Growth Drivers
Australian pharmaceutical manufacturing and supply have been key drivers of growth in FY2025, with continued expansion anticipated in FY2026. Bioxyne is making significant progress in Germany and the UK, and will provide a market update shortly. Additionally, BLSMD40 and BLSMD100 MDMA capsules are set to enter commercial batch production in July.
Future Outlook
Bioxyne is positioned for continued growth in FY2026, driven by further expansion in Australia and entry into high-growth markets including the UK, Germany, and other EU countries.
Motley Fool contributor Lianne Eastty has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.
